The Genetics of Neuropathic Pain from Model Organisms to Clinical Application
- PMID: 31751545
- PMCID: PMC6868508
- DOI: 10.1016/j.neuron.2019.09.018
The Genetics of Neuropathic Pain from Model Organisms to Clinical Application
Abstract
Neuropathic pain (NeuP) arises due to injury of the somatosensory nervous system and is both common and disabling, rendering an urgent need for non-addictive, effective new therapies. Given the high evolutionary conservation of pain, investigative approaches from Drosophila mutagenesis to human Mendelian genetics have aided our understanding of the maladaptive plasticity underlying NeuP. Successes include the identification of ion channel variants causing hyper-excitability and the importance of neuro-immune signaling. Recent developments encompass improved sensory phenotyping in animal models and patients, brain imaging, and electrophysiology-based pain biomarkers, the collection of large well-phenotyped population cohorts, neurons derived from patient stem cells, and high-precision CRISPR generated genetic editing. We will discuss how to harness these resources to understand the pathophysiological drivers of NeuP, define its relationship with comorbidities such as anxiety, depression, and sleep disorders, and explore how to apply these findings to the prediction, diagnosis, and treatment of NeuP in the clinic.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
D.L.B. acknowledges patent application number PCT/GB2017/052909, D.L.B., J.M. Dawes, G. Weir. Method for the treatment or prevention of pain or excessive neuronal activity or epilepsy. D.L.B. has acted as a consultant on behalf of Oxford Innovation for the following companies: Abide, Amgen, Mitsubishi Tanabe, GSK, TEVA, Biogen, Lilly, Orion, and Theranexus. N.B.F. has served in advisory boards of Grünenthal, Novartis Pharma, Teva Pharmaceuticals, Mitshubishi Tanabe Pharma, Merck, and Mundipharma; has received lecture honoraria from Astellas; and receives a research grant from PAINCARE EU Investigational Medicines Initiative (IMI), where the involved companies are Grunenthal, Bayer, Eli Lilly, Esteve, and Teva. A.J.D. acknowledges patent application number PCT/KR2019/00806. R.C.L. serves as chief scientific officer and board member and is an equity holder Onspira Therapeutics, Inc. and acknowledges patent application number PCT/US18/42122: “Methods for Managing Pain.” G.G.N. acknowledges patent application number AU2018902072A0. M. Costigan receives funding from Amgen.
Figures
References
-
- Akopian A.N., Sivilotti L., Wood J.N. A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons. Nature. 1996;379:257–262. - PubMed
-
- Andrews N., Legg E., Lisak D., Issop Y., Richardson D., Harper S., Pheby T., Huang W., Burgess G., Machin I., Rice A.S. Spontaneous burrowing behaviour in the rat is reduced by peripheral nerve injury or inflammation associated pain. Eur. J. Pain. 2012;16:485–495. - PubMed
-
- Argoff C.E. The coexistence of neuropathic pain, sleep, and psychiatric disorders: a novel treatment approach. Clin. J. Pain. 2007;23:15–22. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
